Trishula Therapeutics, Inc.
3 clinical trials · Sponsor
◉ Watch Trishula Therapeutics, Inc.
| Record | Firm | Date |
|---|---|---|
| Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients (NCT06119217) | Trishula Therapeutics, Inc. | 2024-03-25 |
| TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers (NCT04306900) | Trishula Therapeutics, Inc. | 2020-03-30 |
| TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers (NCT03884556) | Trishula Therapeutics, Inc. | 2019-04-10 |
Track Trishula Therapeutics, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.